European Commission approves Novartis’ Itvisma to treat SMA

​

The EC has granted approval for Novartis’ Itvisma as a treatment for children two years and older, teenagers, and adults who have 5q SMA with a bi-allelic mutation in the SMN1 gene.

The post European Commission approves Novartis’ Itvisma to treat SMA appeared first on Hospital Management.

 

Back to the Featured Stories
European Commission approves Novartis’ Itvisma to treat SMA

Featured Stories

First patient enrolled in study of Reflow Medical’s Spur system
Hyperfine launches next-generation Swoop MRI system in Europe
Can-Fite’s Namodenoson meets primary safety endpoints in Phase IIa trial
Inocras, AimedBio team up for cancer treatments
Enrolment concludes in Biohaven’s RISE3 trial for epilepsy

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us